Antigenics announced in June results of an interim analysis from the company's ongoing global patient survival registry, which showed that patients with kidney cancer at intermediate risk of disease recurrence demonstrated an approximately 46 percent lower risk of death when treated with Oncophage.

View press release  |  View PDF of poster (464 K)

The Future for Oncophage^® and for Antigenics (11/20/09)

ABC 7 NEWS
“UCSF patient makes history with brain tumor vaccine” (11/26/09)

Antigenics Receives NASDAQ Delisting Notification (12/31/2009)

European CHMP Formally Adopts Negative Opinion on Oncophage® (11/20/2009)

Antigenics Provides Details On GlaxoSmithKline’s Pivotal Malaria Vaccine Trial With QS-21 Adjuvant (11/4/2009)

Antigenics Reports Third Quarter 2009 Financial Results (10/29/2009)

Data Presented On Oncophage Cancer Vaccine In Recurrent Glioma At SNO 2009 (10/26/2009)

Antigenics to Report Third Quarter 2009 Financial Results on October 29, 2009; Conference Call to Follow (10/22/2009)

Antigenics Announces a Negative Vote From the CHMP on Oncophage® Marketing Application in Europe (10/21/2009)

All events »